A detailed history of Glen Eagle Advisors, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 59 shares of MRNA stock, worth $2,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59
Holding current value
$2,967
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$101.21 - $166.61 $1,214 - $1,999
12 Added 25.53%
59 $7.01 Million
Q1 2024

Jul 03, 2024

BUY
$85.37 - $115.44 $4,012 - $5,425
47 New
47 $5.01 Million
Q2 2023

Aug 13, 2024

SELL
$118.5 - $160.53 $711 - $963
-6 Reduced 10.34%
52 $6.32 Million
Q1 2023

Aug 13, 2024

BUY
$135.66 - $197.02 $1,356 - $1,970
10 Added 20.83%
58 $8.91 Million
Q4 2022

Aug 13, 2024

BUY
$118.38 - $210.04 $236 - $420
2 Added 4.35%
48 $8.62 Million
Q4 2020

Aug 13, 2024

SELL
$65.74 - $169.86 $65 - $169
-1 Reduced 2.13%
46 $4.81 Million
Q3 2020

Aug 13, 2024

SELL
$54.34 - $94.85 $1,738 - $3,035
-32 Reduced 68.09%
15 $1.06 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $19.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.